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Abstract We report a series of breast cancer patients
with invasive skin and nail infections with Staphylococcus
species that we attribute to the addition of pertuzumab to
trastuzumab-based therapy. With the suspicion of an
increased incidence of cutaneous infection in patients
treated with pertuzumab and trastuzumab-based chemo-
therapy, treating medical oncologists identified patients
receiving therapy who experienced infection. Between
March and October 2014, 18 patients treated with pert-
uzumab and trastuzumab-based chemotherapy were found
to have 21 separate skin/nail infections. Treatment was
administered as neoadjuvant therapy in 12 (67 %) patients,
adjuvant therapy in four (22 %) patients, and for metastatic
disease in two (11 %) patients. Granulocyte growth factors
were administered in 11 (61 %) patients and no patients
were documented to be neutropenic. New skin and nail
lesions developed as early as cycle 1 and as late as
8 months from initial therapy. The 21 separate infections
documented were folliculitis and ‘‘bite-like’’ lesions (10),
abscess (6), paronychia (3), and cellulitis (2). The
appearance of these lesions was distinct from typical
EGFR-associated skin changes. When cultures were
obtained, Staphylococcus species were isolated. Quantita-
tive immunoglobulins were assessed in 14 (78 %) patients
and were abnormally low in six (43 %) of these patients.
The skin infections resulted in treatment delay in two
(11 %) patients and premature discontinuation of therapy
in one patient. We believe that the skin/nail infections
reported here in patients treated with the combination of
pertuzumab and trastuzumab represent a previously
unrecognized toxicity of adding pertuzumab to trast-
uzumab-based therapies.
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Introduction
The HER2 protein is an important target for new drug
development. Since the approval of trastuzumab in 1998,
three additional HER2-directed therapies have been added
to the armamentarium— lapatinib, ado-trastuzumab em-
tansine, and pertuzumab [1]. Lapatinib is known to produce
skin and gastrointestinal toxicities that have been attributed
to its dual blockade of HER2 and EGFR signaling [2].
When lapatinib is combined with trastuzumab to treat
metastatic HER2-positive breast cancer, objective respon-
ses are observed even in patients who have previously been
treated with trastuzumab-containing regimens. The toxici-
ties observed with this combination are consistent with an
additive effect of the two agents. Skin rashes and gastro-
intestinal toxicities are common, but no increase in cardiac
toxicity or unanticipated side effects have been reported
[3]. As second-line therapy, ado-trastuzumab emtansine
results in superior disease outcomes and less toxicity than
the combination of lapatinib and capecitabine [4].
Recently, the addition of pertuzumab to trastuzumab and
docetaxel (PTH) has resulted in an improved objective
response rate and significant improvements in both pro-
gression-free survival (PFS) and overall survival without
increased toxicity [5, 6].
The benefit of adding pertuzumab to trastuzumab-based
neoadjuvant chemotherapy was tested in the NEOSPHERE
and TRYPHAENA trials. At the time of surgery, higher
pathologic complete response rates were reported with the
addition of pertuzumab [7, 8]. As a result, the FDA
expanded the indications for pertuzumab to include both
the metastatic and neoadjuvant settings. The NCCN
guideline panel also recommended the addition of pert-
uzumab as adjuvant therapy [9, 10]. With these expanded
indications, more women with HER2-positive breast can-
cers are receiving treatments that combine pertuzumab and
trastuzumab with chemotherapy.
Over the past 12 months, our clinical breast cancer team
became aware that women treated with trastuzumab and
pertuzumab were developing severe Staphylococcus skin
reactions, not previously recognized in the pivotal trials or
evident in the FDA briefing documents [10]. We report the
natural history of what we believe is a previously unrec-
ognized toxicity of these regimens.
Methods
In March 2014, a treating Medical Oncologist identified
unusual and severe Staphylococcus infections in two patients
receiving neoadjuvant PTH (patients 1 and 2). At the weekly
Breast Cancer Research Conference, the cases were dis-
cussed in the context that these skin infections were
potentially related to the addition of pertuzumab to the
conventional regimen of a taxane, with or without carbo-
platin, and trastuzumab. The clinicians agreed to be attentive
and report other patients who developed severe Staphylo-
coccus skin infections. The clinical workup of these patients
was not defined; however, the faculty was encouraged to take
photographs of the skin lesions, and many photographs were
provided by patients as they became concerned about new
skin eruptions. With the identification of hypoglobulinemia
in an early patient, quantitative immunoglobulins were col-
lected on many of the subsequent patients. Antimicrobial
treatment was provided on a case-by-case basis and the
Departments of Infectious Disease and/or Dermatology were
involved in most cases. Attribution of the infection to the
combination of pertuzumab and trastuzumab was made by
the Infectious Disease team.
To rule out the possibility of an institutional outbreak of
Staphylococcus infections, we enlisted the help of the
hospital’s Infection Control team. After an extensive
review, we found no increase in Staphylococcus infections
since the approval of pertuzumab or since the identification
of the first patient reported at City of Hope. Furthermore,
some of the patients we reported were treated at different
locations within the hospital, and two of the patients
received therapy at a community practice site, 15 miles
from the main City of Hope Duarte campus. The lot
numbers for the agents administered were also documented
to be different.
Approval from the IRB was obtained in order to char-
acterize and report what appears to be a previously
unrecognized toxicity of the combination of pertuzumab
and trastuzumab with chemotherapy.
Results
Between March and October 2014, 18 patients with 21
separate skin/nail infections were identified. Their charac-
teristics are summarized in Table 1. The median age was
51 years (range 33–67 years). Twelve (67 %) patients were
treated in the neoadjuvant setting, four (22 %) in the
adjuvant setting, and two (11 %) for metastatic disease.
Ten (56 %) patients were treated with pertuzumab, trast-
uzumab, carboplatin, and docetaxel (PTCH); four (22 %)
with PTH; two (11 %) with pertuzumab, trastuzumab, and
nab-paclitaxel (nabPT); and pertuzumab was added to
maintenance trastuzumab (PH) in the adjuvant setting for
one patient. One patient (patient 12) who was initially
treated with nabPT subsequently received PTCH; follicu-
litis developed while on PTCH. One patient (patient 2)
developed three distinct infections. Of the 21 infectious
episodes, seven developed after cycle 1, four after cycle 2,
two after cycle 3, one after cycle 4, and seven after cycle 6.
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Most patients (12; 67 %) received granulocyte growth
factors within 24–48 h of chemotherapy. No patients were
documented to be neutropenic at the time of presentation
with skin lesions. Cultures were performed on seven
(39 %) patients; methicillin-sensitive Staphylococcus aur-
eus (MSSA) was identified in three (43 %) of these patients
and methicillin-resistant Staphylococcus aureus (MRSA)
in four (57 %) of these patients. The development of skin
lesions resulted in treatment delay in two (11 %) patients.
Of the 12 neoadjuvant patients, eight (67 %) underwent
definitive surgery and six (75 %) of these patients achieved
a pathologic complete response.
Folliculitis involving the face or scalp was identified in
six (33 %) patients with four (22 %) additional patients
experiencing folliculitis and ‘‘bite-like’’ lesions on the arm,
legs, abdomen, and buttocks. Abscesses were identified in
five (28 %) patients, two of whom required incision and
drainage, and one required removal of the portacath.
Severe paronychial infections were seen in three (17 %)
patients and one patient underwent surgical removal of two
nails to facilitate healing. Two patients treated with neo-
adjuvant therapy developed cellulitis following their
definitive local surgery. They are included in this series
because of the rapid and severe nature of the infection and
the documentation of hypogammaglobulinemia. Both were
on maintenance trastuzumab, but had not received pert-
uzumab for 45 and 65 days, respectively. The clinical
appearance was not typical of lapatinib-related skin rashes.
Representative images of skin infections from five patients
are shown in Fig. 1.
Table 1 Patient Characteristics
Pt. Age Setting Regimen Cycle
number
Skin reaction Organism Total Protein/Ig levels
1 51 Neoadjuvant PTH C6D12 Folliculitis—buttocks
Abscess—thumb
MSSA Total protein: 4.7 g/dL
(6.3–8.2 g/dL); C6
Ig: normal; C6D28
2 48 Neoadjuvant PTH C2D6 Abscess—breast – –
C3D6 Abscess—buttocks
and shoulder
MRSA Total protein: 6.2 g/dL
(6.3–8.2 g/dL); C4D10
C4-6 Paronychia – Ig: normal; C5D8
IgG: 661 (700–1,600); C6D17
3 56 Adjuvant PTCH C1D17 Folliculitis—scalp – Ig: normal; C3D1, C6D34
Total protein: 6.1 g/dL
(6.3–8.2 g/dL); C6D23
4 53 Neoadjuvant PTCH C1D15 Folliculitis—scalp – Ig: normal; C4D1
5 49 Adjuvant PTCH C1D20 Folliculitis—abdomen MRSA Total protein: normal
IgM: 38 (38–271); C3D1
6 64 Neoadjuvant PTCH C3D13 Abscess—shoulder
‘‘Bite-like’’ lesions
MRSA Total protein: normal
IgG: 707 (700–1,600); C4D6
7 47 Adjuvant PTCH C1D15 Folliculitis—scalp – –
8 57 Neoadjuvant PTH C2D17 Abscess—buttocks – –
9 46 Neoadjuvant PTCH C6D15 Paronychia—16 nails – IgG: 691 (806–1,813)
IgM: 51 (104-522); C6D38
10 52 Neoadjuvant nabPT C1D2 Abscess—port day 2 MRSA Ig: normal; C3D15
11 51 Metastatic PTH C1D2 ‘‘Bite-like’’ lesions – IgM: 26 (38–271); C2D1
12 33 Metastatic nabPT; PTCH C12D1 Folliculitis—arm MSSA Ig: normal; C12D1
13 36 Adjuvant PH C2D14 Folliculitis—face – Ig: normal; C4D38
14 50 Neoadjuvant PTCH C6D25 Paronychia – Ig: normal; C6D28
15 54 Neoadjuvant PTCH C2D14 Folliculitis—scalp – Ig: normal; C2D15
16 67 Neoadjuvant PTCH C6D46 Seroma with cellulitis – Total protein: 6.1 g/dL; C5D1
IgG: 579 (700–1,600); C6D46
17 38 Neoadjuvant PTCH C1D9 Folliculitis—face – –
18 56 Neoadjuvant nabPT C6D65 Cellulitis MSSA IgG: 556 (700–1,600); C6D65
PTCH pertuzumab, trastuzumab, carboplatin, and docetaxel; PTH pertuzumab, trastuzumab, and docetaxel; nabPT nab-paclitaxel, pertuzumab,
and trastuzumab; PH pertuzumab and trastuzumab; MRSA methicillin-resistant Staphylococcus aureus; MSSA methicillin-sensitive Staphylo-
coccus aureus; C cycle; D day; Pt patient
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Quantitative immunoglobulins were assessed in 14
(78 %) patients and were abnormally low in six (43 %) of
these patients; four after cycle 6 of therapy. Multiple
assessments of quantitative immunoglobulin levels were
performed in three patients and became abnormal over time
in all.
The following cases are representative of the unique
natural history of this process.
Patient 1 is a 51-year-old East Indian woman who
presented with inflammatory breast cancer involving the
left breast, axilla, and supraclavicular lymph nodes.
Treatment with PTH was initially well tolerated until cycle
6, day 7 when she complained of redness of the nose and a
cough. She was not cytopenic and was empirically treated
with a 10-day course of cephalexin and her symptoms
resolved within 3 days. On cycle 6, day 14 while on
cephalexin, she complained of new skin eruptions on the
breast and buttocks that looked like ‘‘insect bites.’’ Over
the subsequent 3 days these lesions increased in size,
became erythematous, pus-filled, and exquisitely painful.
She was seen on day 22 of cycle 6 as she was starting
‘‘maintenance trastuzumab.’’ On that clinic visit, she
received a dose of intravenous vancomycin and trimetho-
prim/sulfamethoxazole was initiated. Three days later, she
was admitted to the hospital with worsening skin lesions.
Cultures from the buttocks and wrist (Fig. 1a, b) grew
Staphylococcus aureus that was sensitive to vancomycin.
Skin biopsies of a new ‘‘bite’’ area and the abscess on the
left wrist demonstrated ‘‘severe acute superficial dermatitis
with interface activity, ulceration and involvement of the
adnexal glands with no evidence of vasculitis.’’ She was
well-nourished; total protein was 4.7 g/dL (6.3–8.2 g/dL).
No further workup was performed and she was discharged
on intravenous vancomycin. All lesions completely
resolved. At mastectomy, 6 mm of residual cancer was
identified in the breast; the skin and all lymph nodes were
without evidence of cancer. Her postoperative course was
uneventful and she continues on maintenance trastuzumab
without recurrence of the skin lesions.
Patient 2 is a 48-year-old African-American woman
who presented with locally advanced breast cancer on the
left with pathologic confirmation of axillary node
involvement. On cycle 2, day 1 of PTCH she noted a
pimple on the contralateral breast. By cycle 2, day 6 the
area had increased in size (Fig. 1c). Although she was
afebrile and had a normal white blood count, cephalexin
was prescribed and the lesion resolved. Following cycle 4,
she noted erythema and swelling on the shoulder and
buttocks. She was prescribed cephalexin on day 3. By cycle
4, day 6 both lesions had increased in size and she was
admitted to the hospital for intravenous vancomycin. The
shoulder lesion was incised and drained. The buttocks
lesion was consistent with cellulitis (Fig. 1d) and no sur-
gical intervention was required. Skin biopsy of the buttocks
demonstrated ‘‘superficial dermatitis and no evidence of
vasculitis.’’ Cultures from the shoulder abscess grew
MRSA and treatment was switched from vancomycin to
daptomycin. Her total protein on admission was 6.2 g/dL
(6.3–8.2 g/dL). Both lesions resolved and she completed
six cycles of chemotherapy without dose or schedule
modification. After cycle 6, she noted pain in her finger and
toenails. Quantitative immunoglobulins were performed on
cycle 5, day 8 and were normal. However, reassessment on
cycle 6, day 17 was abnormal with IgG 661 (700–1,600).
The patient was taken to the operating room where she
was found to have no evidence of tumor. The discomfort in
Fig. 1 Skin/nail infections a Buttocks folliculitis and b wrist abscess
(patient 1); c Early precursor lesions and d buttock cellulitis (patient
2); e Early precursor lesions (patient 11); f Paronychia (patient 14); g
Typical scalp folliculitis (patient 4)
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the finger and toenails continued to worsen postoperatively
and she was able to express pus-like fluid with pressure on
the nail bed. One nail spontaneously fell off; others have
cracked and broken off mid-nail bed. She is tolerating
maintenance trastuzumab and the nails are slowly healing.
Skin biopsies were obtained in four patients. The path-
ologic findings are summarized in Table 2 and represen-
tative biopsies from two patients are shown in Fig. 2.
Although the clinical appearance was atypical of EGFR
inhibitor rashes, the biopsy results are consistent with
findings seen with other EGFR inhibitor cutaneous toxici-
ties. However, since these results are not specific or
pathognomonic, additional biopsies were not obtained in
subsequent patients. The epidermis in all four biopsy
specimens demonstrated areas of compact orthokeratosis
and/or parakeratosis, suggesting altered keratinocyte dif-
ferentiation. Additionally, the inflammation was primarily
periadnexal, which is consistent with other EGFR inhibitor
reactions [11, 12]. Biopsies from patient 1 showed vacuolar
degeneration of the basal layer that has also been seen with
acneiform reactions to EGFR inhibitors (Fig. 2a) [13].
Patient 12 presented with erythematous papules and
pustules on her left arm and abdomen following her elev-
enth cycle of PTCH. Culture from one of the pustules
revealed MSSA and she completely cleared with oral
doxycycline. The lesions recurred several weeks later and
biopsy of a new lesion was performed. It demonstrated
focal parakeratosis with periadnexal inflammation and a
hypoplastic pilosebaceous unit (Fig. 2b). Although non-
specific, these biopsy results are consistent with altered
keratinocyte differentiation seen with EGFR inhibitors.
Discussion
The FDA approval of new agents is made on the basis of
randomized clinical trials where the primary endpoints are
tumor regression or improved PFS and overall survival.
Toxicity is an important component of the approval pro-
cess. However, the toxicity data are generally collected
during the study conduct and are limited by the sample
size. In response to patient demand, the approval process
for new treatments of advanced cancers is shortening [14,
15]. As these agents become available to more patients,
additional side effects become apparent. In fact, half of all
serious adverse events are recognized more than seven
years after FDA approval [16].
This is the first series to report the association of pert-
uzumab, trastuzumab, and chemotherapy with severe
cutaneous staphylococcal infections. In CLEOPATRA, the




1 Left thigh Vacuolar degeneration of basal layer; dense
mixed inflammatory infiltrate involving the
follicles and adnexal structures
Left
breast
Ulceration with vacuolar degeneration of the
basal layer; periadnexal abscess with
predominantly neutrophilic infiltrate and
some giant cells
2 Left hip Hypergranulosis; compact orthokeratosis; mild
superficial perivascular, perineural, and




Focal areas of compact keratosis and
parakeratosis; epidermal spongiosis; intra-
epidermal pustule; abscess within
pilosebaceous unit with dense mixed infiltrate
with numerous neutrophils
15 Scalp Focal compact and orthokeratosis; vacuolar
degeneration of the basal layer; periadnexal
and perifollicular lymphocytic infiltrate with
sparse neutrophils
Fig. 2 Skin biopsies a high-
power view of an H&E-stained





section from patient 12 showing
superficial mild acute
periadnexal inflammation with
concurrent involvement of a
hair follicle (folliculitis) and
sweat glands
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median number of cycles of docetaxel administered was
eight in both arms and the frequency of all adverse effects
was noted to decrease once the docetaxel was discontinued.
However diarrhea, rash, dry skin, neutropenic fever, pru-
ritus, and mucosal inflammation appeared to be more
common in patients assigned to pertuzumab [6]. Nail dis-
orders were reported in 22.9 % of patients in both arms, but
the incidence of grade 3/4 toxicity was higher in patients
receiving pertuzumab, 1.2 % versus 0.3 % [10]. We
believe that severe skin and nail infections with Staphylo-
coccus species are unique side effects resulting from the
addition of pertuzumab to trastuzumab-based chemother-
apy. This toxicity may have gone unrecognized for a
number of reasons. The pertuzumab safety data are derived
from three large randomized clinical trials—CLEO-
PATRA, NEOSPHERE, and TRYPHAENA—that enrolled
patients from many institutions worldwide (Table 3). The
808 patients in CLEOPATRA were enrolled from 205 sites
and 25 countries. NEOSPHERE enrolled 417 patients from
59 sites and 16 countries, and TRYPHAENA enrolled 225
patients from 44 sites and 19 countries [5, 7, 8]. It would be
difficult for an investigator to appreciate a safety signal
with so few patients treated at any one site.
The clinical trial designs for the randomized trials are
summarized in Table 3. Three of the four arms in the
NEOSPHERE trial combined trastuzumab with pert-
uzumab, but each administered only four cycles of therapy.
All three arms of the TRYPHAENA trial utilized pert-
uzumab and trastuzumab, but delivered only three cycles in
one arm and six cycles in two arms. In our series, follic-
ulitis was observed early, however, the more severe
infections and nail infections developed after cycles 3 and
4. In total, the toxicity data for the combination of pert-
uzumab and trastuzumab are based on 846 patients, 556 of
whom received six cycles, 215 four cycles, and 75 three
cycles. Because the addition of lapatinib to trastuzumab
results in a synergistic anti-tumor effect with predictable
normal tissue toxicities, synergistic toxicities from adding
pertuzumab to trastuzumab were not anticipated [3, 17, 18].
The majority of new agents are first tested in patients
with metastatic disease, and it may be difficult to distin-
guish drug toxicity from symptoms of advanced disease.
The musculoskeletal pains that occur with the aromatase
inhibitors were only recognized as a toxicity of the drug
class when they were used in the adjuvant setting [19]. Side
effects that occur in the adjuvant versus neoadjuvant set-
tings are less likely to be attributed to the underlying dis-
ease and safety signals are more apparent. The ongoing
adjuvant APHINITY trial (Table 3) is likely to clarify new
side effects related to the combined antibody therapy.
The development of pustular skin lesions may have been
attributed to the steroid premedication routinely adminis-
tered in patients receiving taxane-based therapies. The skin
lesions described here are not typical of ‘‘steroid acne.’’
Steroid-induced acne generally presents as monomorphic
papules distributed on the upper trunk, arms and less
commonly on the face [20]. Although steroid use is gen-
erally immunosuppressive, the number and severity of
these reactions are unlikely to be attributed to short-course
steroid use alone. Additionally, the prevalence of staphy-
lococcal infections in this population suggests that there is
a specific underlying mechanism. Although the precise
pathogenesis of these reactions is unknown, we propose
several overlapping and synergistic mechanisms.
Both trastuzumab and pertuzumab target HER2, an
epidermal growth factor receptor overexpressed in breast
cancer cells and present in keratinocytes [21]. Although
these agents do not induce the classic acneiform rash seen
with other EGFR inhibitors such as cetuximab and erloti-
nib, the combination therapy is clearly disrupting epider-
mal differentiation in the patients who had biopsies [13].
These results suggest that the combination of trastuzumab
and pertuzumab induces a reaction that is histologically
similar to other EGFR inhibitors, though clinically distinct.
The difference in the morphologies of the reactions is most
likely due to the variability of HER kinase expression in
the skin, nails, and follicles [22, 23]. Similar to other EGFR
inhibitors, this altered epidermal differentiation predis-
poses to infection, primarily by staphylococcal species. In
one study of 221 patients on EGFR inhibitor therapy, 38 %
of the patients had clinical evidence of infection and over
50 % of these were culture positive for staphylococci [24].
The rash and infectious disease complications with these
patients were managed prophylactically with oral antibi-
otics (usually doxycycline or minocycline) plus a topical
steroid to treat the inflammatory component. It may be
beneficial to treat breast cancer patients on combined
therapy with prophylactic measures as well, especially if
we can determine which patients are at the highest risk of
developing infectious complications. Patients who develop
rash with EGFR inhibitor therapy also tend to have better
outcomes [25]. It will be interesting to determine if there is
a similar correlation between pertuzumab and trastuzumab
treatment. The complete pathologic response rate in this
small series suggests that skin/nail infections were neither a
favorable nor an unfavorable predictor or response.
Recent studies have demonstrated that the immunosup-
pressive effect of IVIG may be related to a small per-
centage of glycosylated IgG-Fc present in the preparations
rather than a direct effect of antigen-specific binding [26].
It may be possible that the monoclonal antibodies them-
selves contribute to the immunosuppression seen in these
patients. We did document hypoglobulinemia in six of the
patients. However, many of the affected patients had nor-
mal immunoglobulins at the time of infection and other
patients became hypoglobulinemic with continuation of
568 Breast Cancer Res Treat (2014) 148:563–570
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therapy. Nonetheless, hypoglobulinemia alone does not
explain the mechanism of infection.
The data presented here was derived from cases iden-
tified prospectively only after the patient developed an
infection. We do not have data on the patients who did not
experience any skin reaction. Amongst the group of phy-
sicians who identified the patients with skin infections
reported here, the incidence was 30 %. To minimize any
bias in assigning toxicity to pertuzumab and trastuzumab,
we enlisted the help of specialists in Infectious Disease and
Dermatology, and in three instances, the occurrence of a
skin complication was deemed unrelated to treatment.
Although this was not a prospective clinical trial, we are
convinced that the occurrence of staphylococcal infections
of the skin and nails is a unique toxicity observed when
pertuzumab is added to trastuzumab. We are initiating a
prospective trial to address cutaneous and immunologic
changes in women undergoing treatment with this com-
bined antibody therapy.
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